PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment
Langue
EN
Article de revue
Ce document a été publié dans
Acta Neuropathologica. 2020, vol. 139, n° 6, p. 1025-1044
Résumé en anglais
pinnings, we identified a network of co-expressed proteins connecting PLCG2 to APOE and TREM2 using unsupervised co-regulatory network analysis. The network was highly enriched for the complement cascade and genes ...Lire la suite >
pinnings, we identified a network of co-expressed proteins connecting PLCG2 to APOE and TREM2 using unsupervised co-regulatory network analysis. The network was highly enriched for the complement cascade and genes differentially expressed in disease-associated microglia. Our data show that p.P522R in PLCG2 reduces AD disease progression by mitigating tau pathology in the presence of amyloid pathology and, as a consequence, maintains cognitive function. Targeting the enzyme PLCG2 might provide a new therapeutic approach for treating AD.< Réduire
Mots clés
SEPIA
HEALTHY
Unités de recherche